Lupin shares in focus on receiving European Commission approval for biosimilar ranibizumab

In a regulatory filing on Monday, the drug maker stated that it received approval for Ranluspec for use in vials and pre-filled syringes, following the positive opinion from the Committee for Medicinal Products for Human Use.

The biosimilar ranibizumab will be commercialised by Sandoz across the European Union, excluding Germany, it stated.

In France, the product will be commercialised by two companies, Sandoz and Biogaran, Lupin added.

According to the company, ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A.

Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization, the statement noted.

Commenting on the development, Thierry Volle, President EMEA and Emerging Markets, Lupin, said: “We are very pleased to receive the European Commission approval for ranibizumab. This achievement underscores the strength and quality of our scientific capabilities and manufacturing excellence. We remain firmly committed to expanding access to innovative, high-quality, and affordable biologic therapies for underserved patients worldwide.”

Dr. Cyrus Karkaria, President of Biotechnology at Lupin, stated that the approval from the European Commission for its biosimilar ranibizumab “is a milestone that validates our unwavering commitment and scientific standards to making advanced biologic therapies more accessible.”

The stock closed 0.99% higher at ₹2,241.40 per equity share on Monday.

The scrip has gained more than 1% in the past week and 5% over the month. On a year-to-date basis, it has surged 7%.

While Lupin shares hit a 52-week high of ₹2,263 on February 17, 2025, they touched a year’s low of ₹1,795.20 per unit on April 7, 2025.

Lupin has a total market capitalisation of ₹1.03 lakh crore, as of February 23, 2026, according to data on the NSE.